Caligan Partners’s Artiva Biotherapeutics ARTV Stock Holding History

Caligan Partners’s Portfolio ARTV Stock Details ARTV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$16.8M	Buy	+1,736,111	New	+$15.8M	0.79%	22

Other funds holding ARTV

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return

Caligan Partners's ARTV Position: Q2 2026 in Review

Caligan Partners opened a new position in Artiva Biotherapeutics (ARTV) in Q2 2026: 1,736,111 shares worth $16.8M. The stake represents 0.79% of the portfolio and ranks #22 among its holdings.

65 funds tracked by Wall St. Rank hold ARTV as of Q2 2026.

Caligan Partners held 1,736,111 shares of Artiva Biotherapeutics worth $16.8M as of Q2 2026.
Artiva Biotherapeutics was a new Caligan Partners position in Q2 2026.
Artiva Biotherapeutics made up 0.79% of Caligan Partners's portfolio in Q2 2026, its #22 holding.
65 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q2 2026.

Based on Caligan Partners's 13F filing for Q2 2026, filed 14 Aug 2026.